Cover Image
市場調查報告書

氣喘預防藥的全球市場的展望

Preventive Asthma Drug Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 346849
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
氣喘預防藥的全球市場的展望 Preventive Asthma Drug Market Outlook 2020
出版日期: 2015年12月07日 內容資訊: 英文 45 Pages
簡介

現在,全球有約3億名氣喘患者。另一方面,到目前為止的研究開發 (R&D) 活動,有各種抑制氣喘發作的醫藥品開發、上市。全球製藥企業進一步推動研究活動,著手開發氣喘的預防藥。2014年時,全球氣喘預防藥的市場規模估計為220億美元。

本報告提供全球氣喘預防藥的市場相關分析、疾病概要,及主要推動及阻礙市場要素、今後的市場趨勢預測、各產品/各地區的詳細趨勢、市場最新趨勢與發展的方向性、主要企業簡介競爭力 (SWOT分析) 等相關調查。

第1章 分析師的見解

第2章 分析方法

第3章 氣喘:概要

第4章 推動因素與課題

  • 推動市場要素
    • 醫療費用支出額的增加
    • 老年人口的增加
    • 氣喘的患病人數的增加
    • 研究開發 (R&D) 的活躍造成技術創新
  • 課題
    • 高額的藥物成本
    • 藥物的副作用
    • 開發中國家市場上的需求很少
    • 不完全的認知度

第5章 氣喘預防藥市場分析

第6章 市場區隔

  • 藥物的各類型
  • 各地區

第7章 市場趨勢和動靜

  • 對氣喘患者有正面作用的聯合治療
  • 單株抗體:創新的、有效的氣喘治療方法
  • 氣喘追蹤工具的疾病管理支援

第8章 競爭力評估

  • 主要企業的市場佔有率
  • 銷售額前幾名的氣喘預防藥
  • 簡介
    • Glaxosmithkline
    • Astrazeneca
    • Merck
    • Roche
    • Novartis

第9章 建議

圖表一覽

目錄

Asthma is showing high prevalence worldwide. About 300 Million people are suffering from asthma. This is due to continuously deteriorating air quality, which is causing several allergies. In recent years, researchers have explored wide variety of preventive drugs that can delay asthma attacks. These drugs are being highly acknowledged by the doctors and consumers. The practice of prescribing preventive drugs by doctors is gaining momentum in the US, Europe and Asia-Pacific. Foreseeing the demand, several pharma players are shifting their R&D focus towards preventive asthma drugs. Some of the leading players in the pharma industry include Glaxosmithkline, Astrazeneca, Merck, Novartis, Roche, and others. The drugs by these players contributed millions of dollars to their revenue in 2014.

In its latest research, “Preventive Asthma Drug Market Outlook 2020”, RNCOS presents a comprehensive analysis of the industry. The report covers key drivers & challenges, and trends & developments that are peculiar to the drug market. The research includes estimated market figures of 2014, and forecasted numbers till 2020. The market was estimated at US$ 22 Billion in 2014. Our analysts have segmented the preventive asthma drug industry depending on the type of drugs and geographical distribution. A separate section is allotted to the competitive landscape, including the business overview of the key players and their SWOT analysis.

Our research revealed that inhaled corticosteroids were the most popular category of preventers during 2014. Researchers are combining corticosteroids with other form of drugs, such as long acting beta agonists in a single inhaler. The so called “combination therapy” is providing several benefits over the single dose. However, the market is facing few challenges like side-effects posed by such drugs, their high cost and lack of awareness in India, China, and other Middle East & Asia-Pacific countries.

Towards the end, RNCOS has suggested some recommendations to boost the preventers market in the coming future. On the whole, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the preventive asthma drugs industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Asthma - An Introduction

4. Drivers & Challenges

  • 4.1. Drivers
    • 4.1.1. Rising Healthcare Expenditure
    • 4.1.2. Growing Geriatric Population
    • 4.1.3. Increasing Prevalence of Asthma
    • 4.1.4. Increasing R&D Driving Innovation
  • 4.2. Challenges
    • 4.2.1. High Cost of Drugs
    • 4.2.2. Side Effects Caused By Drugs
    • 4.2.3. Limited Demand from Developing Markets
    • 4.2.4. Inadequate Awareness

5. Preventive Asthma Drugs Market Overview

6. Market Segmentation

  • 6.1. By Type of Drugs
  • 6.2. By Geography

7. Trends & Developments

  • 7.1. Combined Therapy Benefitting Asthma Patients
  • 7.2. Monoclonal Antibody: An Emerging Effective Treatment for Asthma
  • 7.3. Asthma Tracking Tool Aiding Disease Management

8. Competitive Assessment

  • 8.1. Market Share of Key Players
  • 8.2. Top Selling Preventive Asthma Drugs
  • 8.3. Profiles
    • 8.3.1. Glaxosmithkline
    • 8.3.2. Astrazeneca
    • 8.3.3. Merck
    • 8.3.4. Roche
    • 8.3.5. Novartis

9. Recommendations

List of Figures:

  • Figure 3-1: Diagnostic Flow - Chart for Asthma in Clinical Practices
  • Figure 5-1: Global - Preventive Asthma Drugs Market (Billion US$), 2014-2020
  • Figure 6-1: Global - Preventive Asthma Drugs Market by Different Types of Drugs (%), 2014
  • Figure 6-2: Global - Preventive Asthma Drugs Market by Geography (%), 2014
  • Figure 8-1: Share of Major Players in Preventive Asthma Drugs Market (%), 2014
  • Figure 8-2: Glaxosmithkline Plc - Revenue by Geographical Regions (%), 2014
  • Figure 8-3: Astrazeneca - Revenue by Geographical Regions (%), 2014
  • Figure 8-4: Merck - Revenue by Geographical Regions (%), 2014
  • Figure 8-5: Roche - Revenue by Geographical Regions (%), 2014
  • Figure 8-6: Novartis - Revenue by Geographical Regions (%), 2014

List of Tables:

  • Table 8-1: Revenues of Top Selling Preventive Asthma Drugs (Million US$), 2014
  • Table 8-2: Glaxosmithkline Plc - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 8-3: Astrazeneca - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 8-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 8-5: Roche: Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 8-6: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
Back to Top